Zentalis Pharmaceuticals stock gains 10.32 percent after Leerink upgrade
Published on 10/06/2026 at 14:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Zentalis Pharmaceuticals stock (ISIN US98943L1070) was last at USD 2.78 on Nasdaq on October 5, 2026, up 10.32 percent from the prior close. The move followed Leerink Partners' new Outperform rating and USD 8.00 price target, replacing its previous Market Perform view and USD 4.00 target, as Yahoo Finance reported on October 5, 2026.
Leerink doubles its target
The change takes the analyst target from USD 4.00 to USD 8.00, a 100 percent increase. Leerink's thesis centers on azenosertib, Zentalis' investigational oral WEE1 inhibitor for platinum-resistant ovarian cancer, giving the stock a clinical-data focus rather than a revenue-growth story.
The market reaction came with ZNTL at USD 2.78, while the same October 5 session showed an open of USD 2.69, a high of USD 2.83 and a low of USD 2.62. The USD 197.9 million market capitalization and 2,992,671-share volume underline the small-cap profile of the company.
Loss widens the execution test
Zentalis reported a diluted EPS loss of USD 0.59 for Q2 2026, versus a USD 0.49 consensus estimate, a miss of USD 0.10, according to MarketBeat on October 5, 2026. The finance figures show a Q2 net loss of USD 42.286 million and operating cash flow of negative USD 37.236 million for the quarter ended June 30, 2026.
That contrast defines the setup: the valuation case depends on clinical progress while the company remains loss-making. Zentalis' investor-relations profile describes a clinical oncology program built around azenosertib and biomarker-driven treatment studies, including monotherapy and combination trials, as stated on its investor-relations page.
Consensus meets October data dates
MarketBeat lists a consensus Hold rating from 10 analysts, with five Buy, four Hold and one Sell recommendations, plus an average 12-month target of USD 6.75. At USD 2.78, that target lies 142.4 percent above the October 5 price, while ZNTL's 52-week range is USD 1.21 to USD 6.95.
The next visible test is clinical rather than financial. Yahoo Finance reported that Zentalis is scheduled to present DENALI Part 1b overall-survival data at the European Society for Medical Oncology Congress on October 23, 2026, followed by an ASPENOVA trial-in-progress poster on October 26, 2026.
ZNTL stock closes near its yearly midpoint
ZNTL was last at USD 2.78 on Nasdaq at 4:00 p.m. ET on October 5, 2026, leaving the stock 59.9 percent below its 52-week high of USD 6.95 and 129.8 percent above its low of USD 1.21. The figures frame a binary biotech setup: the stock has recovered from its yearly floor, but clinical execution remains the central valuation variable.
Zentalis Pharmaceuticals stock facts
- Company: Zentalis Pharmaceuticals, Inc.
- ISIN: US98943L1070
- Ticker: ZNTL
- Trading venue: NASDAQ
- Price (as of October 5, 2026, 4:00 p.m. ET): USD 2.78
- Market capitalization: USD 197.9 million (as of October 5, 2026)
- 52-week range: USD 1.21-6.95 (as of October 5, 2026)
- Sector / Industry: Health care / Biotechnology
Upcoming dates for Zentalis Pharmaceuticals stock
- October 23, 2026: DENALI Part 1b overall-survival presentation at the ESMO Congress
- October 26, 2026: ASPENOVA trial-in-progress poster at the ESMO Congress
